P22 virus-like particles as an effective antigen delivery nanoplatform for cancer immunotherapy

Li, Wenjing; Jing, Zhe; Wang, Shuqing; Li, Qiyu; Xing, Yanfeng; Shi, Heng; Li, Shuang; Hong, Zhangyong

doi:10.1016/j.biomaterials.2021.120726

Cited by 52 publications

(42 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Advantages Of Protein Nanoparticles For Cancer Nanomedicinementioning

confidence: 99%

“…It is normal to obtain VLPs using self-assembly [ 113 , 114 ]. Hong et al used the self-assembly method to prepare VLPs originating from bacteriophage P22 [ 115 ]. The model antigen peptide was displayed onto the coat protein (CP), which was then self-assembled with the scaffolding protein (SP) to get the P22 VLP-Antigen Peptide with an icosahedral structure.…”

Section: Design Of Protein Nanoparticlesmentioning

confidence: 99%

“…(2) Given the numerous epitopes and microstructures on the surface of proteins, the modification and production for improving the function of nanoparticles are relatively easy. Especially, a genetic engineering strategy can be used to display antigen epitopes or other functional groups on the protein nanoparticles for cancer nanomedicine [ 115 , 125 – 127 ]. (3) Protein is naturally amphipathic, enabling the hydrophobic domain of proteins to interact with lots of hydrophobic anti-tumor drugs for improving the drug encapsulation capability of nanoparticles.…”

Section: Design Of Protein Nanoparticlesmentioning

confidence: 99%

See 2 more Smart Citations

Protein nanoparticles directed cancer imaging and therapy

Miao

Yang

et al. 2022

Nano Convergence

View full text Add to dashboard Cite

Cancer has been a serious threat to human health. Among drug delivery carriers, protein nanoparticles are unique because of their mild and environmentally friendly preparation methods. They also inherit desired characteristics from natural proteins, such as biocompatibility and biodegradability. Therefore, they have solved some problems inherent to inorganic nanocarriers such as poor biocompatibility. Also, the surface groups and cavity of protein nanoparticles allow for easy surface modification and drug loading. Besides, protein nanoparticles can be combined with inorganic nanoparticles or contrast agents to form multifunctional theranostic platforms. This review introduces representative protein nanoparticles applicable in cancer theranostics, including virus-like particles, albumin nanoparticles, silk protein nanoparticles, and ferritin nanoparticles. It also describes the common methods for preparing them. It then critically analyzes the use of a variety of protein nanoparticles in improved cancer imaging and therapy.

show abstract

Section: Advantages Of Protein Nanoparticles For Cancer Nanomedicinementioning

confidence: 99%

Section: Design Of Protein Nanoparticlesmentioning

confidence: 99%

Section: Design Of Protein Nanoparticlesmentioning

confidence: 99%

See 1 more Smart Citation

Protein nanoparticles directed cancer imaging and therapy

Miao

Yang

et al. 2022

Nano Convergence

View full text Add to dashboard Cite

show abstract

“…Bone marrow-derived dendritic cells (BMDCs) were prepared as previously described (37,57). Brie y, bone marrow (BM) cells were isolated by ushing femurs and tibias of C57BL/6 mice and red blood cells (RBC) were depleted by ACK lysis (Gibco, A10492-01).…”

Section: Preparation Of Cd11c + Mouse Bmdc Cellsmentioning

confidence: 99%

An all-in-one adjuvanted therapeutic cancer vaccine targeting dendritic cell cytosol induces long-lived tumor suppression through NLRC4 inflammasome activation

Puth

Verma

Hong

et al. 2021

Preprint

View full text Add to dashboard Cite

Therapeutic cancer vaccines (TCVs) should induce robust tumor-specific T cell responses. To achieve this, TCVs incorporate T cell epitopes and strong adjuvants. Here, we report an all-in-one adjuvanted cancer vaccine platform, which targets intracellular compartment of antigen presenting cells and subsequently induces effective cytotoxic T cell responses. We screened a novel peptide (DCpep6) that specifically binds and tranmits into CD11c+ cells through in vivo phage biopanning. We then engineered a protein-based TCV (DEF) consisting of DCpep6 (D), an optimized HPV E7 tumor antigen (E), and a built-in flagellin adjuvant (F) as a single molecule. DEF was stably expressed and each component was functional. In vivo administered DEF rapidly biodistributed in draining LNs and internalized into CD11c+ cells. DEF immunization elicited strong anti-tumor T cell responses and provided long-term survival of TC-1 tumor implanted mice. The DEF-mediated anti-tumor effect was abolished in NLRC4−/− mice. Taken together, we propose a protein-based all-in-one TCV platform that intracellularly co-delivers tumor antigen and inflammasome activator to DCs to induce long-lasting anti-tumor T cell responses.

show abstract

“…For antibody sensors, the generation and characterization of new antibodies are time consuming and difficult, 19,20 such as induction by target preparations, animal immunity, antibody purification, and other operations are complicated and require time and material costs. [21][22][23] For some small molecules and proteins with low immunogenicity, it is also difficult for newly generated antibodies to control their binding properties and bind to similar structures to cause non-target interference, 24 and are easily affected by immunosuppressive agents. 25 Different from enzyme and antibody sensors, the most notable feature of aptamers is their ease of modification and low immunogenicity.…”

Section: Introductionmentioning

confidence: 99%